© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 21, 1593-1602,
November 1, 1995
© 1995 Oxford University Press
Decreased Mutation Rate for Cellular Resistance to Doxorubicin and Suppression of mdrl Gene Activation by the Cyclosporin PSC 833
Affiliations of authors: Divisions of Oncology and Clinical Pharmacology, Department of Medicine, Stanford University School of Medicine Stanford, CA
Correspondence to: Branimir I. Sikic, M.D., Oncology Division, Stanford University Medical Center, Rm. M-211. Stanford, CA 94305-5306.
Background: Various mechanisms can contribute to cellular resistance to doxorubicin. These include expression of the multidrug transporter P-glycoprotein (product of the mdr1 gene [also known as PGY1]), Mrp (multidrug resistance-associated protein), the p110 major vault protein, altered glutathione metabolism, and altered levels or activity of topoisomerase II (Topo II). We reported recently that singlestep treatment of human MES-SA sarcoma cells with 40 nM doxorubicin resulted in selection of spontaneous mutants at a rate of 1.8 x 10–6 per cell generation. All individually selected mutants manifested the multidrug-resistant phenotype, related to activation of the mdrl gene. Purpose: Luria and Delbrück fluctuation analysis was performed with MES-SA cells to determine the mutation rate and the nature and mechanisms of resistance after single-step selection with doxorubicin in the presence of the cyclosporin PSC 833, a potent modulator of multidrug resistance. Methods: Ten flasks were seeded with 2000 cells/flask and grown to confluent populations of approximately 8 x 106 cells. After reseeding in 96-well plates, the populations were treated with 40 nM doxorubicin and 2 µM PSC 833 for 3 weeks. Surviving colonies were scored, individually harvested, and propagated. The drug-resistant phenotype was assessed by the tetrazolium dye (MTT) cytotoxicity assay and by monitoring cellular glutathione content and radiolabeled drug accumulation. Coupled reverse transcription-polymerase chain reaction (RT-PCR) was used to evaluate mdr1, MRP, Topo II
, and Topo II
gene expression. Topo II, P-glycoprotein, and p110 levels were examined by immunoblotting or immunocytochemstry. Topo II activity was assessed by decatenation of kinetoplast DNA, and etoposide-induced cleavable complex formation was studied by the potassium-sodium dodecyl sulfate precipitation assay. Results: Mutations were detected at a rate of 2.5 x 10–7 per cell generation. Analysis of variance indicates that spontaneous mutations, rather than changes in cellular function, conferred resistance to doxorubicin and PSC 833. None of the isolated clones expressed mdr1 messenger RNA or P-glycoprotein, and none exhibited an increase in MRP expression. No alterations were found in cellular glutathione content, intracellular accumulations of daunorubicin and etoposide, levels of p110 protein, or levels of Topo II transcripts. However, a significant decrease in Topo II messenger RNA and protein was found in all examined clones, as well as decreased Topo II catalytic activity and reduced cleavable complex formation in the presence of etoposide. Conclusions: PSC 833 co-selection reduced the mutation rate for doxorubicin-selected resistance by 10-fold and suppressed the emergence of mdr1 mutants. Survival of cells exposed to doxorubicin and PSC 833 occurs by selection of spontaneously arising mutants that exhibit altered Topo II expression. Implications: Our results suggest that treatment with multidrug resistance modulators such as PSC 833 together with multidrug resistance-related cytotoxins may suppress the activation of mdr1 and prevent the emergence of resistant cancer cell clones with the multidrug-resistant phenotype. [J Natl Cancer Inst 1995;87:1593–1602]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Lhomme, F. Joly, J. L. Walker, A. A. Lissoni, M. O. Nicoletto, G. M. Manikhas, M. M.O. Baekelandt, A. N. Gordon, P. M. Fracasso, W. L. Mietlowski, et al. Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer J. Clin. Oncol., June 1, 2008; 26(16): 2674 - 2682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Chen, Y. C. Wang, M. E. Schaner, B. Francisco, G. E. Duran, D. Juric, L. M. Huff, H. Padilla-Nash, T. Ried, T. Fojo, et al. Genetic and Epigenetic Modeling of the Origins of Multidrug-Resistant Cells in a Human Sarcoma Cell Line Cancer Res., October 15, 2005; 65(20): 9388 - 9397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Qadir, K. L. O'Loughlin, S. M. Fricke, N. A. Williamson, W. R. Greco, H. Minderman, and M. R. Baer Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator Clin. Cancer Res., March 15, 2005; 11(6): 2320 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Munoz-Martinez, P. Lu, F. Cortes-Selva, J. M. Perez-Victoria, I. A. Jimenez, A. G. Ravelo, F. J. Sharom, F. Gamarro, and S. Castanys Celastraceae Sesquiterpenes as a New Class of Modulators That Bind Specifically to Human P-Glycoprotein and Reverse Cellular Multidrug Resistance Cancer Res., October 1, 2004; 64(19): 7130 - 7138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Piekarz, R. W. Robey, Z. Zhan, G. Kayastha, A. Sayah, A. H. Abdeldaim, S. Torrico, and S. E. Bates T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance Blood, June 15, 2004; 103(12): 4636 - 4643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Leonard, T. Fojo, and S. E. Bates The Role of ABC Transporters in Clinical Practice Oncologist, October 1, 2003; 8(5): 411 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Peters and J. M. Brown Tirapazamine: A Hypoxia-activated Topoisomerase II Poison Cancer Res., September 15, 2002; 62(18): 5248 - 5253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Murren Modulating Multidrug Resistance: Can We Target this Therapy? Clin. Cancer Res., March 1, 2002; 8(3): 633 - 635. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Fracasso, M. F. Brady, D. H. Moore, J. L. Walker, P. G. Rose, L. Letvak, T. M. Grogan, and W. P. McGuire Phase II Study of Paclitaxel and Valspodar (PSC 833) in Refractory Ovarian Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., June 15, 2001; 19(12): 2975 - 2982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baekelandt, G. Lehne, C. G. Trope, I. Szanto, P. Pfeiffer, B. Gustavssson, and G. B. Kristensen Phase I/II Trial of the Multidrug-Resistance Modulator Valspodar Combined With Cisplatin and Doxorubicin in Refractory Ovarian Cancer J. Clin. Oncol., June 15, 2001; 19(12): 2983 - 2993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Advani, G. A. Fisher, B. L. Lum, J. Hausdorff, J. Halsey, M. Litchman, and B. I. Sikic A Phase I Trial of Doxorubicin, Paclitaxel, and Valspodar (PSC 833), a Modulator of Multidrug Resistance Clin. Cancer Res., May 1, 2001; 7(5): 1221 - 1229. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Newman, J. C. Rodarte, K. D. Benbatoul, S. J. Romano, C. Zhang, S. Krane, E. J. Moran, R. T. Uyeda, R. Dixon, E. S. Guns, et al. Discovery and Characterization of OC144-093, a Novel Inhibitor of P-Glycoprotein-mediated Multidrug Resistance Cancer Res., June 1, 2000; 60(11): 2964 - 2972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V. Dahl, N. J. Lacayo, N. Brophy, K. Dunussi-Joannopoulos, H. J. Weinstein, M. Chang, B. I. Sikic, and R. J. Arceci Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients With Recurrent or Refractory Acute Myeloid Leukemia J. Clin. Oncol., May 9, 2000; 18(9): 1867 - 1875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Chen, N. J. Lacayo, G. E. Durán, D. Cohen, and B. I. Sikic Loss of Cyclosporin and Azidopine Binding Are Associated with Altered ATPase Activity by a Mutant P-glycoprotein with Deleted Phe335 Mol. Pharmacol., April 1, 2000; 57(4): 769 - 777. [Abstract] [Full Text]
|
|
|
|
|
|
S. E. Bates Drug Resistance: Still on the Learning Curve Clin. Cancer Res., November 1, 1999; 5(11): 3346 - 3348. [Full Text] [PDF]
|
|
|
|
|
|
E. J. Lee, S. L. George, M. Caligiuri, T. P. Szatrowski, B. L. Powell, S. Lemke, R. K. Dodge, R. Smith, M. Baer, and C. A. Schiffer Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420 J. Clin. Oncol., September 1, 1999; 17(9): 2831 - 2831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Advani, H. I. Saba, M. S. Tallman, J. M. Rowe, P. H. Wiernik, J. Ramek, K. Dugan, B. Lum, J. Villena, E. Davis, et al. Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar) Blood, February 1, 1999; 93(3): 787 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chen, G. E. Duran, K. A. Steger, N. J. Lacayo, J.-P. Jaffrezou, C. Dumontet, and B. I. Sikic Multidrug-resistant Human Sarcoma Cells with a Mutant P-Glycoprotein, Altered Phenotype, and Resistance to Cyclosporins J. Biol. Chem., February 28, 1997; 272(9): 5974 - 5982. [Abstract] [Full Text] [PDF]
|
|